{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:38:53Z","timestamp":1792625933676,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["N42A690510"],"award-info":[{"award-number":["N42A690510"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-026-02249-2","type":"journal-article","created":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T04:05:28Z","timestamp":1785038728000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Heterogeneity in the treatment effect of sodium-glucose cotransporter-2 inhibitor on chronic kidney disease risk reduction: a prevalent new user cohort study applying double\/debiased machine learning"],"prefix":"10.1186","volume":"18","author":[{"given":"Tanawan","family":"Kongmalai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panu","family":"Looareesuwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2040-7970","authenticated-orcid":false,"given":"Amarit","family":"Tansawet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukanya","family":"Siriyotha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patratorn","family":"Kunakorntham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burin","family":"Boonwatcharapai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth J.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammarin","family":"Thakkinstian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,26]]},"reference":[{"key":"2249_CR1","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/s41591-022-01790-7","volume":"28","author":"ATN Nair","year":"2022","unstructured":"Nair ATN, Wesolowska-Andersen A, Brorsson C, et al. Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes. Nat Med. 2022;28:982\u20138.","journal-title":"Nat Med"},{"key":"2249_CR2","doi-asserted-by":"crossref","unstructured":"Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, Group US. Risk factors for renal dysfunction in type 2 diabetes: U.K. prospective diabetes study 74. Diabetes. 2006;55:1832\u20131839.","DOI":"10.2337\/db05-1620"},{"key":"2249_CR3","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"2249_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117\u201327.","journal-title":"N Engl J Med"},{"key":"2249_CR5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"2249_CR6","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice C. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S158-S78.","DOI":"10.2337\/dc24-S009"},{"key":"2249_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/bmj.316.7126.201","volume":"316","author":"B Sibbald","year":"1998","unstructured":"Sibbald B, Roland M. Understanding controlled trials. Why are randomised controlled trials important? BMJ. 1998;316:201.","journal-title":"BMJ"},{"key":"2249_CR8","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1542\/hpeds.2022-006690","volume":"12","author":"SS Wallace","year":"2022","unstructured":"Wallace SS, Barak G, Truong G, Parker MW. Hierarchy of evidence within the medical literature. Hosp Pediatr. 2022;12:745\u201350.","journal-title":"Hosp Pediatr"},{"key":"2249_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12874-022-01768-6","volume":"22","author":"F Liu","year":"2022","unstructured":"Liu F, Panagiotakos D. Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Med Res Methodol. 2022;22:287.","journal-title":"BMC Med Res Methodol"},{"key":"2249_CR10","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1016\/S0140-6736(95)90120-5","volume":"345","author":"PM Rothwell","year":"1995","unstructured":"Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet. 1995;345:1616\u20139.","journal-title":"Lancet"},{"key":"2249_CR11","doi-asserted-by":"crossref","unstructured":"Angus DC, Chang C-CH. Heterogeneity of treatment effect: estimating how the effects of interventions vary across individuals. JAMA. 2021;326:2312\u20132313.","DOI":"10.1001\/jama.2021.20552"},{"key":"2249_CR12","doi-asserted-by":"publisher","first-page":"5961","DOI":"10.1002\/sim.9154","volume":"40","author":"J Hoogland","year":"2021","unstructured":"Hoogland J, IntHout J, Belias M, et al. A tutorial on individualized treatment effect prediction from randomized trials with a binary endpoint. Stat Med. 2021;40:5961\u201381.","journal-title":"Stat Med"},{"key":"2249_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jclinepi.2020.05.022","volume":"125","author":"TL Nguyen","year":"2020","unstructured":"Nguyen TL, Collins GS, Landais P, Le Manach Y. Counterfactual clinical prediction models could help to infer individualized treatment effects in randomized controlled trials-An illustration with the international stroke trial. J Clin Epidemiol. 2020;125:47\u201356.","journal-title":"J Clin Epidemiol"},{"key":"2249_CR14","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1017\/ice.2023.214","volume":"45","author":"A Tansawet","year":"2024","unstructured":"Tansawet A, Siribumrungwong B, Techapongsatorn S, et al. Delayed versus primary closure to minimize risk of surgical-site infection for complicated appendicitis: a secondary analysis of a randomized trial using counterfactual prediction modeling. Infect Control Hosp Epidemiol. 2024;45:322\u20138.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2249_CR15","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1002\/sim.9090","volume":"40","author":"L Hu","year":"2021","unstructured":"Hu L, Ji J, Li F. Estimating heterogeneous survival treatment effect in observational data using machine learning. Stat Med. 2021;40:4691\u2013713.","journal-title":"Stat Med"},{"key":"2249_CR16","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jama.2024.2933","volume":"331","author":"KG Buell","year":"2024","unstructured":"Buell KG, Spicer AB, Casey JD, et al. Individualized treatment effects of oxygen targets in mechanically ventilated critically ill adults. JAMA. 2024;331:1195\u2013204.","journal-title":"JAMA"},{"key":"2249_CR17","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S0895-4356(96)00002-9","volume":"49","author":"JV Tu","year":"1996","unstructured":"Tu JV. Advantages and disadvantages of using artificial neural networks versus logistic regression for predicting medical outcomes. J Clin Epidemiol. 1996;49:1225\u201331.","journal-title":"J Clin Epidemiol"},{"key":"2249_CR18","first-page":"507","volume-title":"The economics of artificial intelligence: an agenda","author":"A S","year":"2019","unstructured":"S A. The impact of machine learning on economics. In: Agrawal A, Agrawal A, Goldfarb A, editors. The economics of artificial intelligence: an agenda. Chicago: University of Chicago Press; 2019. p. 507\u201352."},{"key":"2249_CR19","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1111\/ectj.12097","volume":"21","author":"V Chernozhukov","year":"2018","unstructured":"Chernozhukov V, Chetverikov D, Demirer M, et al. Double\/debiased machine learning for treatment and structural parameters. Econom J. 2018;21:C1\u201368.","journal-title":"Econom J"},{"key":"2249_CR20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1093\/ectj\/utaa027","volume":"24","author":"V Semenova","year":"2020","unstructured":"Semenova V, Chernozhukov V. Debiased machine learning of conditional average treatment effects and other causal functions. Econom J. 2020;24:264\u201389.","journal-title":"Econom J"},{"key":"2249_CR21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344\u20139.","journal-title":"J Clin Epidemiol"},{"key":"2249_CR22","unstructured":"Scikit-learn. Available from: https:\/\/scikit-learn.org\/stable\/install.html. [Accessed 4th June 2026]"},{"key":"2249_CR23","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ejor.2023.09.018","volume":"313","author":"B Bokelmann","year":"2024","unstructured":"Bokelmann B, Lessmann S. Improving uplift model evaluation on randomized controlled trial data. Eur J Oper Res. 2024;313:691\u2013707.","journal-title":"Eur J Oper Res"},{"key":"2249_CR24","unstructured":"Kidney Disease \u2013 Improving Global Outcome (KDIGO) collaborative group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S126."},{"issue":"1","key":"2249_CR25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/biomet\/asn055","volume":"96","author":"RK Crump","year":"2009","unstructured":"Crump RK, Hotz VJ, Imbens GW, Mitnik OA. Dealing with limited overlap in estimation of average treatment effect. Biometrika. 2009;96(1):187\u201399.","journal-title":"Biometrika"},{"issue":"6","key":"2249_CR26","first-page":"1887","volume":"45","author":"J Textor","year":"2016","unstructured":"Textor J, van der Zander B, Gilthorpe MK, et al. Robust causal inference using directed acyclic graphs: the R package \u2018dagitty.\u2019 Int J Epidemiol. 2016;45(6):1887\u201394.","journal-title":"Int J Epidemiol"},{"key":"2249_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167:268\u201374.","journal-title":"Ann Intern Med"},{"key":"2249_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1536867X241233641","volume":"24","author":"A Ahrens","year":"2024","unstructured":"Ahrens A, Hansen CB, Schaffer ME, Wiemann T. Ddml: double\/debiased machine learning in Stata. Stata J. 2024;24:3\u201345.","journal-title":"Stata J"},{"key":"2249_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-34505-0","volume":"13","author":"T Mizuguchi","year":"2023","unstructured":"Mizuguchi T, Sawamura S. Machine learning-based causal models for predicting the response of individual patients to dexamethasone treatment as prophylactic antiemetic. Sci Rep. 2023;13:7549.","journal-title":"Sci Rep"},{"key":"2249_CR30","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s00125-024-06099-3","volume":"67","author":"P Cardoso","year":"2024","unstructured":"Cardoso P, Young KG, Nair ATN, et al. Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Diabetologia. 2024;67:822\u201336.","journal-title":"Diabetologia"},{"key":"2249_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-023-02207-2","volume":"23","author":"A Venkatasubramaniam","year":"2023","unstructured":"Venkatasubramaniam A, Mateen BA, Shields BM, et al. Comparison of causal forest and regression-based approaches to evaluate treatment effect heterogeneity: an application for type 2 diabetes precision medicine. BMC Med Inform Decis Mak. 2023;23:110.","journal-title":"BMC Med Inform Decis Mak"},{"key":"2249_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1079725","author":"K Siddiqui","year":"2022","unstructured":"Siddiqui K, George TP, Joy SS, Alfadda AA. Risk factors of chronic kidney disease among type 2 diabetic patients with longer duration of diabetes. Front Endocrinol (Lausanne). 2022. https:\/\/doi.org\/10.3389\/fendo.2022.1079725.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2249_CR33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2147\/IJNRD.S489891","volume":"17","author":"EDS Goicochea-Rios","year":"2024","unstructured":"Goicochea-Rios EDS, Yupari-Azabache IL, Otiniano NM, G\u00f3mez Goicochea NI. Associated factors for chronic kidney disease in patients with diabetes mellitus 2: retrospective study. Int J Nephrol Renovasc Dis. 2024;17:289\u2013300.","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2249_CR34","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12933-022-01641-2","volume":"21","author":"S Siriyotha","year":"2022","unstructured":"Siriyotha S, Lukkunaprasit T, Looareesuwan P, et al. Effects of second-line antihyperglycemic drugs on the risk of chronic kidney disease: applying a target trial approach to a hospital-based cohort of Thai patients with type 2 diabetes. Cardiovasc Diabetol. 2022;21:248.","journal-title":"Cardiovasc Diabetol"},{"key":"2249_CR35","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s13098-024-01522-6","volume":"16","author":"A Tansawet","year":"2024","unstructured":"Tansawet A, Looareesuwan P, Teza H, et al. Effects of sodium-glucose cotransporter-2 inhibitors on chronic kidney disease progression: a multi-state survival model. Diabetol Metab Syndr. 2024;16:281.","journal-title":"Diabetol Metab Syndr"}],"container-title":["Diabetology & Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-026-02249-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02249-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02249-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:59:05Z","timestamp":1792623545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-026-02249-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,26]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2249"],"URL":"https:\/\/doi.org\/10.1186\/s13098-026-02249-2","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,26]]},"assertion":[{"value":"4 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of the Faculty of Medicine Ramathibodi Hospital, Mahidol University (MURA2022\/474, MURA2021\/522). According to the study design, written informed consent from patients was waived off by the committee.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"221"}}